Apixaban Is Safe and Effective in Morbidly Obese Patients: A Retrospective Analysis of 390 Patients with BMI ≥40

Background: In patients with venous thromboembolism (VTE), warfarin had been considered standard of care until the new direct oral anticoagulants (DOACs) were developed. Studies in patients with acute VTE and non-valvular atrial fibrillation (AF) have shown comparable therapeutic efficacy and a similar or lower bleeding risk for DOACs when compared to warfarin. However, low representation of obese patients in these studies and the unknown effect...